PreOmics, founded in 2016 and headquartered in Germany, has become a pivotal part of the Biognosys Group as of 2025. The company's slogan, "SETTING THE STANDARD FOR PROTEIN ANALYSIS," highlights its core focus on enhancing proteomics through innovation and high-performance solutions.
The Biognosys Group, which includes PreOmics, Biognosys, and biocrates, is leading the charge in multiomics, integrating cutting-edge consumables, software, and instruments. This synergy delivers seamless mass spectrometry workflows. Their vendor-neutral approach broadens compatibility across major platforms, driving open collaboration in the scientific community.
PreOmics received a Series B investment of €13.50M in January 2022, backed by Bruker Corp.. This support underscores a strong alignment with strategic growth in the analytics and biotechnology sectors, offering scalable and flexible business models that adapt to diverse laboratory needs.